Presbyopia News

The FDA has accepted a new drug application for CSF-1 for the treatment of presbyopia, according to a press release from Orasis Pharmaceuticals.

We now have more than a year’s worth of experience with Vuity, the first pharmaceutical FDA approved for the treatment of age-related blurry vision or presbyopia.

As presbyopia-correcting IOLs continue to evolve, it is exciting to see lens manufacturers find additional ways to improve the optical performance of these lenses.

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, William B. Trattler, MD, explains considerations for choosing a presbyopia-correcting IOL and which patients may not be best suited for them.

KOLOA, Hawaii — Finding the right candidate for receiving a presbyopia-correcting IOL can be challenging, as is choosing the best IOL for that candidate, William B. Trattler, MD, said at Hawaiian Eye 2023.

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, Paul Smith of Orasis Pharmaceuticals discusses phase 3 data for the CSF-1 eye drop for presbyopia treatment following its new drug application submission to the FDA.

I’ve said it before: There are four stages of life. First, you believe in Santa Claus. Next, you stop believing in Santa Claus. Next, you are Santa Claus, and finally, you begin to look like Santa Claus.

The decision to move to a permanent surgical treatment for presbyopia is an individual choice. It depends on the patient’s exams, their stage of life, the way their eyes are aging and their ultimate goals.

Few visual impairments have as far a reach as presbyopia.

Presbyopia is the second most common refractive error we deal with as ophthalmologists, myopia being No. 1. Approximately 128 million people in the United States and 2 billion people globally have presbyopia.